RxDoctor Payments DataLook up a doctor →

Craig Thurm, MD

Pulmonary Disease · Jamaica, NYNPI 1174585681

Payments from drug & device makers

$624,365in general payments, 2019–2025

Across 585 payments — averaging $1067.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$157K
  • Regeneron Healthcare Solutions, Inc.$152K
  • Sanofi$125K
  • Johnson & Johnson$46K
  • Mylan Specialty L.p.$46K
  • Boehringer Ingelheim$25K
  • plus $74K from 13 others

What the payments were for

  • Consulting fees$30,8345%
  • Speaking & faculty fees$503,62183%
  • Travel & lodging$57,89710%
  • Food & beverage$11,3542%
  • Education$1350%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$624,365 in reported general payments places this provider in the 95th percentile of 1,115 pulmonary disease providers in New York.

See all pulmonary disease providers in New York

Medicare billing

Part B allowed, 2024
$19,825
Medicare patients
76
Services billed
359

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate36$492,218
Dupixent SyringeDupilumab22$79,528
Dupixent PenDupilumab16$55,908
TezspireTezepelumab-Ekko13$55,689
Trelegy ElliptaFluticasone/Umeclidin/Vilanter65$47,435
NucalaMepolizumab11$38,630
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr51$28,734
Breztri AerosphereBudesonide/Glycopyr/Formoterol20$13,780
Breo ElliptaFluticasone/Vilanterol17$10,033
Incruse ElliptaUmeclidinium Bromide26$8,731
Spiriva RespimatTiotropium Bromide11$5,597
Albuterol Sulfate HfaAlbuterol Sulfate107$3,757
SymbicortBudesonide/Formoterol Fumarate12$3,267
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate19$3,088
Mycophenolate Mofetil16$1,026

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat$25,045$497,81547 claims
GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Breo Ellipta, Incruse Ellipta$157,223$133,563170 claims
AstraZenecaTezspire, Breztri Aerosphere, Symbicort$15,571$72,73645 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,115 pulmonary disease providers in New York.

Other pulmonary disease in Jamaica

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →